Overcoming the cost challenge of rare, orphan & genetic therapies and CGT development

Craig Caceci, Managing Director, Terebellum®, walks us through how to overcome the cost challenge of CGT development for rare, orphan and genetic therapies

3.5 million people in the UK are living with a rare condition, which is defined as one that affects less than one in every 2000. Because around 80% of these conditions are genetic in origin, they are often treated via cell and gene therapies (CGT) – CGT development is vital to these rare conditions.

To read more, click here.